Human BMPR2/SMAD1584-Luc Reporter Cell Line - HEK293

The Human BMPR2/SMAD1584-Luc Reporter Cell Line - HEK293 is an advanced in vitro model built upon the well-established Human Embryonic Kidney 293 (HEK293) lineage. Renowned for their reliable adherent growth, classic epithelial morphology, and high transfection efficiency, HEK293 cells provide a stable host for complex genetic engineering. This specific reporter line is precisely modified to stably overexpress the human Bone Morphogenetic Protein Receptor Type 2 (BMPR2)—a critical transmembrane serine/threonine kinase receptor. Concurrently, the cells feature a stably integrated firefly luciferase (Luc) reporter gene under the strict transcriptional control of a minimal promoter containing specific Bone Morphogenetic Protein (BMP) response elements. Biologically, when a specific BMP ligand binds to the BMPR2 complex, it triggers the phosphorylation of downstream receptor-regulated SMADs, specifically SMAD1, SMAD5, and SMAD8. These activated R-SMAD proteins then form a heteromeric complex with the common-mediator SMAD4 and translocate directly into the nucleus. The active SMAD1/5/8/4 complex binds to the engineered promoter sequence, initiating the transcription of the luciferase enzyme to generate a robust, quantifiable bioluminescent signal that accurately reflects the functional activation of the BMP signaling axis.

The highly responsive and dynamic nature of this engineered cell line makes it a vital tool for fundamental signal transduction research and targeted drug discovery pipelines. In laboratory settings, the bioluminescent output serves as a highly sensitive, real-time metric for continuously quantifying BMPR2 pathway activation. This establishes an optimal platform for the high-throughput screening (HTS) of novel pharmacological agents, including recombinant BMP ligands, pathway modulators, and small-molecule kinase inhibitors. Because deficient or aberrant BMPR2 signaling is fundamentally implicated in severe systemic pathologies—most notably Pulmonary Arterial Hypertension (PAH), where BMPR2 loss-of-function mutations are the primary genetic driver, as well as various osteogenesis and bone remodeling disorders—accurately monitoring its activity is clinically paramount. By enabling researchers to directly quantify functional intracellular SMAD signaling without relying on labor-intensive, low-throughput diagnostic assays like Western blotting for phosphorylated proteins, this reporter line significantly accelerates the preclinical development, screening, and validation of therapeutics aimed at restoring or modulating the BMP pathway.